| Unbound MEDLINE results for: | Bookmark this site | | Articles related to 18815563 [Unique ID], provided by the PubMed system | |
| |
|
| | 1 - 10 of 100 journal articles in the PubMed database | Email to a friend | | |
| Woltering EA, O'Dorisio TM, Vinik A, et al.
Octreotide LAR in Carcinoid: How to Dose? [JOURNAL ARTICLE]
Pancreas 2008 Oct; 37(3):338-339.
Full Citation | Find Related Articles | | Rubin J, Ajani J, Schirmer W, et al.
Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome. [Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial]
J Clin Oncol 1999 Feb; 17(2):600-6.
Abstract | Full Citation | Find Related Articles | | Garland J, Buscombe JR, Bouvier C, et al.
Sandostatin LAR (long-acting octreotide acetate) for malignant carcinoid syndrome: a 3-year experience. [Journal Article]
Aliment Pharmacol Ther 2003 Feb; 17(3):437-44.
Abstract | Full Citation | Find Related Articles | | Woltering EA, Mamikunian PM, Zietz S, et al.
Effect of octreotide LAR dose and weight on octreotide blood levels in patients with neuroendocrine tumors. [Journal Article]
Pancreas 2005 Nov; 31(4):392-400.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Woltering EA, Salvo VA, O'Dorisio TM, et al.
Clinical value of monitoring plasma octreotide levels during chronic octreotide long-acting repeatable therapy in carcinoid patients. [Journal Article]
Pancreas 2008 Jul; 37(1):94-100.
Abstract | Full Citation | Find Related Articles | | Tomassetti P, Migliori M, Corinaldesi R, et al.
Treatment of gastroenteropancreatic neuroendocrine tumours with octreotide LAR. [Journal Article]
Aliment Pharmacol Ther 2000 May; 14(5):557-60.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Woltering EA, Hilton RS, Zolfoghary CM, et al.
Validation of Serum Versus Plasma Measurements of Chromogranin A Levels in Patients With Carcinoid Tumors: Lack of Correlation Between Absolute Chromogranin A Levels and Symptom Frequency. [JOURNAL ARTICLE]
Pancreas 2006 Oct; 33(3):250-254.
Abstract | Full Citation | | Turner HE, Thornton-Jones VA, Wass JA
Systematic dose-extension of octreotide LAR: the importance of individual tailoring of treatment in patients with acromegaly. [Journal Article]
Clin Endocrinol (Oxf) 2004 Aug; 61(2):224-31.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Turner HE, Vadivale A, Keenan J, et al.
A comparison of lanreotide and octreotide LAR for treatment of acromegaly. [Journal Article]
Clin Endocrinol (Oxf) 1999 Sep; 51(3):275-80.
Abstract | Full Citation | Publisher Full Text | Find Related Articles |   |
|
| | Enter
www.unboundmedicine.com/medline
in your iPhone browser
or View our
Unbound MEDLINE
iPhone demo
Advertise on this site.
|
